Inhibiting Mycobacterium abscessus Cell Wall Synthesis: Using a Novel Diazabicyclooctane β-Lactamase Inhibitor To Augment β-Lactam Action
Journal article published in 2022 by
Khalid M. Dousa 
,
David C. Nguyen ,
Sebastian G. Kurz,
Magdalena A. Taracila,
Christopher R. Bethel,
William Schinabeck,
Barry N. Kreiswirth ,
Sheldon T. Brown,
W. Henry Boom,
Richard S. Hotchkiss,
Kenneth E. Remy ,
Frank J. Jacono,
Charles L. Daley,
Steven M. Holland,
Alita A. Miller
and other authors.
,
David C. Nguyen ,
Sebastian G. Kurz,
Magdalena A. Taracila,
Christopher R. Bethel,
William Schinabeck,
Barry N. Kreiswirth ,
Sheldon T. Brown,
W. Henry Boom,
Richard S. Hotchkiss,
Kenneth E. Remy ,
Frank J. Jacono,
Charles L. Daley,
Steven M. Holland,
Alita A. Miller
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
Durlobactam (DUR) is a potent inhibitor of Bla Mab and provides protection of amoxicillin and imipenem against hydrolysis. DUR has intrinsic activity and forms stable acyl-enzyme complexes with Ldt Mab2 and Ldt Mab4 . The ability of DUR to protect amoxicillin and imipenem against Bla Mab and its intrinsic activity along with the dual β-lactam target redundancy can explain the rationale behind the potent activity of this combination.